The Effect of Nasal Continuous Positive Airway Pressure Treatment on PTSD Symptoms.
Hypothesis #1. We hypothesize that prevention of SDB among PTSD patients with nasal CPAP will result improve their anxiety, insomnia and alcohol craving (among those who use alcohol to control their symptoms).
Hypothesis #2. We hypothesize that the change in symptoms among the PTSD patients participating in the study will be paralleled by a change in the total of sleep stage shifts observed during polysomnography.
|Study Design:||Observational Model: Case-Crossover
Time Perspective: Prospective
|Official Title:||The Effect of Nasal Continuous Positive Airway Pressure (Nasal CPAP) Treatment on Post Traumatic Stress Disorder (PTSD) Symptoms.|
- The Effect of nasal Continuous Positive Airway Pressure (nasal CPAP) Treatment on Post Traumatic Stress Disorder (PTSD) Symptoms. [ Time Frame: six weeks of nasal CPAP ] [ Designated as safety issue: No ]A comparison of the effectiveness of six weeks of nasal CPAP plus usual care to usual care alone at decreasing the symptoms of PTSD (anxiety, insomnia and alcohol craving) among veterans with PTSD and SDB
- The Effect of nasal Continuous Positive Airway Pressure (nasal CPAP) Treatment on Post Traumatic Stress Disorder (PTSD) Symptoms. [ Time Frame: 6 weeks of nasal CPAP ] [ Designated as safety issue: No ]A comparison of the change in symptoms to the change in the total of sleep stage shifts during sleep for all patients with PTSD and SDB participating in the study.
|Study Start Date:||March 2010|
|Estimated Study Completion Date:||January 2015|
|Estimated Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
Design: This is a pilot study to study the effect of nasal CPAP on the symptoms of PTSD in veterans.
Veterans with PTSD will be recruited from the Northport VAMC PTSD unit. The ACOS/Mental Health will refer patients that meet inclusion criteria and do not have an impaired decision making capacity. Subjects will be screened for decision-making capacity by their treating psychiatrist as part of their clinical assessment upon admission to the PTSD unit.
This will be a prospective, randomized, controlled interventional trial:
- Participants will undergo a routine clinical sleep study at the PTSD unit (using a portable polysomnographic recording unit).
Participants who demonstrate SDB will be randomized into two groups based upon their body mass index
- Group A: BMI < 30 kg/m2
- Group B: BMI > 30 kg/m2 The reason for these two arms is to study the effect of nasal CPAP upon PTSD symptoms in veterans with a high prevalence of sleep apnea ( BMI above 30 kg/m2) and in veterans with predominantly snoring (BMI below 30 kg/m2). This distinction is important because in Dr Amin's GWI research, reviewers argued that the nasal CPAP was not having a specific effect on GWI, but treating sleep apnea in GWI patients resulting in nonspecific improvement in GWI symptoms.
Each group will then be randomized into two sub-groups regarding treatment.
- Treatment group receives an automated CPAP unit to use during sleep for 6 weeks in conjunction with their usual care in the PTSD unit (psychotherapy).
- Control group receives the usual care that is provided in the PTSD unit for 6 weeks (change in medications will exclude the subject from the study), if any participant in the control group would like to try nasal CPAP, then he will be crossed over to use an automated CPAP unit during sleep for his second 6 weeks in the PTSD unit together with usual care.
All participants will fill out the following questionnaires at baseline and after 6 weeks. (Those in the control group who have been crossed-over to nasal CPAP will also fill out a set of questionnaire at 12 weeks).
- PTSD checklist-military version (anxiety)
- MASQ anxious arousal subscale (anxiety)
- Insomnia Severity Index (insomnia)
- The alcohol craving questionnaire (with an alcohol history during the intake) All participants will undergo portable polysomnography with their assigned treatment at baseline and at the end of 6 weeks of their participation. All those in the control group who cross-over to nasal CPAP will also undergo portable polysomnography at 12 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01512771
|Contact: Mohammad M Amin, MD||631 261 4400 ext firstname.lastname@example.org|
|United States, New York|
|PTSD unit at Northport VAMC||Recruiting|
|Northport, New York, United States, 11768|
|Contact: Dorothy Baker 631-261-4400 ext 2850 Dorothy.Baker3@va.gov|
|Principal Investigator:||Mohammad Amin, MD||Northport VAMC|